

Omid Hamid

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6337848/publications.pdf>

Version: 2024-02-01

64
papers

45,670
citations

57758

44
h-index

123424

61
g-index

64
all docs

64
docs citations

64
times ranked

39553
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers. <i>Clinical Cancer Research</i> , 2022, 28, 71-83.	7.0	37
2	Optimal systemic therapy for high-risk resectable melanoma. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 431-439.	27.6	12
3	The “Great Debate” at Immunotherapy Bridge 2021, December 1st–2nd, 2021. <i>Journal of Translational Medicine</i> , 2022, 20, 179.	4.4	0
4	Quantitative metastatic lymph node burden and survival in Merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 312-320.	1.2	17
5	Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. <i>European Journal of Cancer</i> , 2021, 144, 182-191.	2.8	57
6	Improved survival in women versus men with merkel cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 321-329.	1.2	26
7	Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2656-2666.	1.6	145
8	Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. <i>New England Journal of Medicine</i> , 2021, 385, 1196-1206.	27.0	376
9	Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. <i>European Journal of Cancer</i> , 2021, 157, 391-402.	2.8	13
10	Letter Regarding Editorial by Samuel Zagarella. <i>American Journal of Dermatopathology</i> , 2021, 43, 539-541.	0.6	2
11	Longitudinal SARS-CoV-2 mRNA Vaccine-Induced Humoral Immune Responses in Patients with Cancer. <i>Cancer Research</i> , 2021, 81, 6273-6280.	0.9	30
12	Association of <i>BRAF</i> V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma. <i>JAMA Oncology</i> , 2020, 6, 1256.	7.1	38
13	P865...Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update. , 2020, , .		3
14	Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 5869-5878.	7.0	131
15	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab Response. <i>Clinical Cancer Research</i> , 2020, 26, 2436-2436.	7.0	4
16	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020, 26, 4201-4205.	7.0	30
17	Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. <i>Clinical Cancer Research</i> , 2020, 26, 4531-4541.	7.0	46
18	The association between facility volume and overall survival in patients with Merkel cell carcinoma. <i>Journal of Surgical Oncology</i> , 2020, 122, 254-262.	1.7	6

#	ARTICLE	IF	CITATIONS
19	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	2.8	132
20	Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1239-1251.	10.7	812
21	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
22	Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma. <i>Cancers</i> , 2019, 11, 1642.	3.7	47
23	Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of Atezolizumab. <i>Clinical Cancer Research</i> , 2019, 25, 6061-6072.	7.0	58
24	Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2018, 24, 4960-4967.	7.0	222
25	Long-Term Outcomes in Patients With <i>BRAF</i> V600E-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	1.6	196
26	Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. <i>British Journal of Cancer</i> , 2018, 119, 670-674.	6.4	114
27	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	27.0	983
28	5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9516-9516.	1.6	32
29	Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1249-1264.	4.2	56
30	Pulse Dose Erlotinib and Zuckerguss Improvement in EGFR-Mutant NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1857-1858.	1.1	0
31	Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). <i>Lancet</i> , The, 2017, 390, 1853-1862.	13.7	1,032
32	Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. <i>European Journal of Cancer</i> , 2017, 86, 37-45.	2.8	183
33	Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1600.	7.4	857
34	Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. <i>European Journal of Cancer</i> , 2016, 67, 46-54.	2.8	77
35	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	27.0	1,140
36	Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3119-3125.	1.6	755

#	ARTICLE	IF	CITATIONS
37	Overall Survival and Durable Responses in Patients With <i>BRAF</i> V600E-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2016, 34, 871-878.	1.6	266
38	Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. <i>Journal of Clinical Oncology</i> , 2016, 34, 1510-1517.	1.6	627
39	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	1.6	517
40	Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9504-9504.	1.6	44
41	Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. <i>Lancet Oncology</i> , The, 2015, 16, 908-918.	10.7	1,419
42	Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 2018-2028.	27.0	5,183
43	Pembrolizumab versus Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2015, 372, 2521-2532.	27.0	4,838
44	Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 1889-1894.	1.6	1,809
45	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq1 1 0,784314 rgrBT /Over	10.7	1,093
46	Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600E-Mutant Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4023-4031.	1.6	430
47	Survival, safety, and response patterns in a phase 1b multicenter trial of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9063-9063.	1.6	23
48	Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels. <i>Frontiers in Oncology</i> , 2014, 4, 110.	2.8	51
49	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <i>Nature</i> , 2014, 515, 563-567.	27.8	4,342
50	Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With <i>BRAF</i> V600E-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor. <i>Journal of Clinical Oncology</i> , 2014, 32, 3697-3704.	1.6	173
51	Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. <i>Lancet</i> , The, 2014, 384, 1109-1117.	13.7	1,588
52	Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 847-861.	3.1	110
53	Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma. <i>New England Journal of Medicine</i> , 2013, 369, 134-144.	27.0	3,128
54	Sunitinib Therapy for Melanoma Patients with <i>KIT</i> Mutations. <i>Clinical Cancer Research</i> , 2012, 18, 1457-1463.	7.0	197

#	ARTICLE	IF	CITATIONS
55	Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer. New England Journal of Medicine, 2012, 366, 2455-2465.	27.0	6,820
56	Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management. Current Oncology Reports, 2012, 14, 441-448.	4.0	138
57	An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunology, Immunotherapy, 2012, 61, 1019-1031.	4.2	703
58	Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunology, Immunotherapy, 2012, 61, 733-737.	4.2	84
59	Ipilimumab (IPI) in metastatic castrate-resistant prostate cancer (mCRPC): Results from an open-label, multicenter phase I/II study.. Journal of Clinical Oncology, 2012, 30, 25-25.	1.6	11
60	A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. Journal of Translational Medicine, 2011, 9, 204.	4.4	500
61	Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immunity, 2010, 10, 9.	3.2	89
62	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma. Clinical Cancer Research, 2009, 15, 5591-5598.	7.0	531
63	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. Clinical Cancer Research, 2009, 15, 7412-7420.	7.0	2,857
64	Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). Cancer, 2007, 110, 2614-2627.	4.1	275